OS Therapies (OSTX) Intangibles (2023 - 2024)
OS Therapies' (OSTX) quarterly Intangibles came in at $7355.0 in Q1 2024, down 8.63% on a QoQ basis from $8050.0 in Q4 2023.
OS Therapies (OSTX) Intangibles (2023 - 2024) Analysis & Trends
OS Therapies (OSTX) has 2 years of Intangibles data on file, last reported at $7355.0 in Q1 2024.
- Quarterly Intangibles changed N/A year-over-year to $7355.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $7355.0 (changed N/A YoY) and the FY2023 annual result came in at $8050.0, changed N/A from the prior year.
- Intangibles fell to $7355.0 in Q1 2024, from $8050.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $8050.0 in Q4 2023 to a low of $7355.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | - |
| 10 | OS Therapies | 19.93 Mn | 19.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 7,355.00 |
| Dec 31, 2023 | 8,050.00 |